Literature DB >> 6347779

A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control.

G Krzentowski, A Scheen, M Castillo, A S Luyckx, P J Lefèbvre.   

Abstract

Interruption of a continuous subcutaneous insulin infusion, most often due to technical problems occurring during the night, is a not uncommon event whose metabolic consequences have received relatively little attention until now. We have therefore investigated the changes in blood glucose, plasma non-esterified fatty acids, 3-hydroxybutyrate, glucagon and free insulin in eight C-peptide negative Type 1 diabetic patients whose pumps were deliberately stopped between 23.00 h and 05.00 h. A control test with the pump functioning normally was carried out in each patient and the studies were randomized. Considering the values at 23.00 h as reference, interruption of the insulin infusion resulted in (1) a rapid decrease in plasma free insulin significant after 1 h and reaching a nadir of 6 +/- 2 mU/l after 6 h; (2) a rise in blood glucose which was significant at hour 3 and reached 17.4 +/- 1.9 mmol/l at hour 6; (3) a moderate increase in plasma nonesterified fatty acids which remained in the range of 700-800 mumol/l; (4) an early and linear rise in plasma 3-hydroxybutyrate, significant after 1 h and averaging 1290 +/- 140 mumol/l after 6 h; (5) a late increase (hour 5) in plasma glucagon. The second aim of our study was to provide for the patient a precise scheme of insulin supplements administered via the pump and based on blood glucose monitoring (Dextrostix - Glucometer) and semi-quantitative evaluation of ketonuria (Acetest). Resetting the pump at its basal rate at 05.00 h and giving insulin supplements (2-8 U) at 06.45 h (with the usual breakfast dose) and again at 10.00 h have proved efficacious in restoring satisfactory metabolic control by noon the day after starting the experiment. These results form practical recommendations to patients undergoing this type of accident.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6347779     DOI: 10.1007/bf00251815

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  15 in total

1.  Microdetermination of long-chain fatty acids in plasma and tissues.

Authors:  V P DOLE; H MEINERTZ
Journal:  J Biol Chem       Date:  1960-09       Impact factor: 5.157

2.  [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (author's transl)].

Authors:  J Pirart
Journal:  Diabete Metab       Date:  1977-06

3.  A simple method for the determination of serum free insulin levels in insulin-treated patients.

Authors:  S Nakagawa; H Nakayama; T Sasaki; K Yoshino; Y Y Yu
Journal:  Diabetes       Date:  1973-08       Impact factor: 9.461

Review 4.  Regulation of hepatic fatty acid oxidation and ketone body production.

Authors:  J D McGarry; D W Foster
Journal:  Annu Rev Biochem       Date:  1980       Impact factor: 23.643

5.  Practical problems with insulin pumps.

Authors: 
Journal:  N Engl J Med       Date:  1982-06-03       Impact factor: 91.245

6.  Current status of portable insulin infusion devices. Satellite workshop on portable insulin infusion devices. (Preceding the XVth annual meeting of the European Society for Clinical Investigation) 18-19 March 1981, Basel, Switzerland.

Authors:  U Keller; D S Schade
Journal:  Diabetologia       Date:  1981-10       Impact factor: 10.122

7.  Radioimmunological determination of human C-peptide in serum.

Authors:  L G Heding
Journal:  Diabetologia       Date:  1975-12       Impact factor: 10.122

8.  Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon.

Authors:  J E Gerich; M Lorenzi; D M Bier; V Schneider; E Tsalikian; J H Karam; P H Forsham
Journal:  N Engl J Med       Date:  1975-05-08       Impact factor: 91.245

9.  Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia.

Authors:  J C Pickup; H Keen; J A Parsons; K G Alberti
Journal:  Br Med J       Date:  1978-01-28

10.  Continuous subcutaneous insulin infusion: improved blood-glucose and intermediary-metabolite control in diabetics.

Authors:  J C Pickup; H Keen; J A Parsons; K G Alberti; A S Rowe
Journal:  Lancet       Date:  1979-06-16       Impact factor: 79.321

View more
  11 in total

1.  Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.

Authors:  A J Scheen; J Gillet; J Rosenthaler; J Guiot; P Henrivaux; B Jandrain; P J Lefèbvre
Journal:  Diabetologia       Date:  1989-11       Impact factor: 10.122

2.  Diabetic ketoacidosis: current views on pathogenesis and treatment.

Authors:  U Keller
Journal:  Diabetologia       Date:  1986-02       Impact factor: 10.122

3.  Innovations in technology for the treatment of diabetes: clinical development of the artificial pancreas (an autonomous system).

Authors:  David C Klonoff; Charles L Zimliki; Lcdr Alan Stevens; Patricia Beaston; Arleen Pinkos; Sally Y Choe; Guillermo Arreaza-Rubín; William Heetderks
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

4.  Ketone production in children with type 1 diabetes, ages 4-14 years, with and without nocturnal insulin pump suspension.

Authors:  R Paul Wadwa; H Peter Chase; Dan Raghinaru; Bruce A Buckingham; Irene Hramiak; David M Maahs; Laurel Messer; Trang Ly; Tandy Aye; Paula Clinton; Craig Kollman; Roy W Beck; John Lum
Journal:  Pediatr Diabetes       Date:  2016-07-12       Impact factor: 4.866

5.  A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 2. Marked attenuation of the metabolic deterioration by somatostatin.

Authors:  A J Scheen; G Krzentowski; M Castillo; P J Lefèbvre; A S Luyckx
Journal:  Diabetologia       Date:  1983-05       Impact factor: 10.122

6.  Metabolic effects of insulin in a human model of ketoacidosis combining exposure to lipopolysaccharide and insulin deficiency: a randomised, controlled, crossover study in individuals with type 1 diabetes.

Authors:  Mads V Svart; Nikolaj Rittig; Ulla Kampmann; Thomas S Voss; Niels Møller; Niels Jessen
Journal:  Diabetologia       Date:  2017-04-07       Impact factor: 10.122

7.  Low subcutaneous degradation and slow absorption of insulin in insulin-dependent diabetic patients during continuous subcutaneous insulin infusion at basal rate.

Authors:  D J Chisholm; E W Kraegen; M J Hewett; S Furler
Journal:  Diabetologia       Date:  1984-08       Impact factor: 10.122

8.  Continuous subcutaneous insulin infusion in diabetes mellitus. A year's prospective trial.

Authors:  A G Davies; D A Price; C A Houlton; J L Burn; B A Fielding; R J Postlethwaite
Journal:  Arch Dis Child       Date:  1984-11       Impact factor: 3.791

Review 9.  Closed-loop insulin delivery for treatment of type 1 diabetes.

Authors:  Daniela Elleri; David B Dunger; Roman Hovorka
Journal:  BMC Med       Date:  2011-11-09       Impact factor: 8.775

10.  Frequency of morning ketosis after overnight insulin suspension using an automated nocturnal predictive low glucose suspend system.

Authors:  Roy W Beck; Dan Raghinaru; R Paul Wadwa; H Peter Chase; David M Maahs; Bruce A Buckingham
Journal:  Diabetes Care       Date:  2014       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.